ArticleJournal of lifestyle medicine2025
Matairesinol Treatment Interferes with the Replication of Coronavirus.
Article in Journal of lifestyle medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spread of a coronavirus infection can result in a pandemic, similar to the coronavirus disease 2019 pandemic. Such an infection also accounts for a considerable portion of common cold cases. Although coronavirus medicines are already available, alternative treatments are still required as the coronavirus can produce many variants. Matairesinol, a lignan family compound, is the constituent of cereals, such as rye. We used the human coronavirus OC43 to evaluate the antiviral activity of matairesinol. Matairesinol treatment interferes with coronavirus replication. This treatment decreases the expression of coronavirus protein and RNA as well as the number of coronavirus-induced plaque formations. Our experimental results collectively indicate that matairesinol treatment can potentially reduce coronavirus replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.